Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer

Modern Pathology

Volumn 24, Issue 6, 2011, Pages 794-800

  Koh, Young Wha ^a   Lee, Hee Jin ^a   Lee, Jong Won ^a   Kang, Jun ^b   Gong, Gyungyub ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Military Manpower Administration   (South Korea)

Author keywords

breast cancer; fluorescence in situ hybridization; HER2; silver enhanced in situ hybridization

Indexed keywords

TUMOR MARKER;

ARTICLE; BREAST CANCER; COLOR; DIAGNOSTIC VALUE; DUAL COLOR SILVER ENHANCED IN SITU HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; VALIDATION STUDY;

ADENOCARCINOMA; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SILVER STAINING; TUMOR MARKERS, BIOLOGICAL;

EID: 79957892140     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.9     Document Type: Article

References (21)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
3. Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36. (Pubitemid 46039831)
4. Gruver AM, Peerwani Z, Tubbs RR. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol 2010;63:210-219.
5. Francis GD, Jones MA, Beadle GF, et al. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 2009;18:88-95.
6. Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol 2009;18:96-102.
7. Kang J, Kwon GY, Lee YH, et al. Comparison of silver-enhanced in situ hybridization and fluorescence in situ hybridization for HER2 gene status in breast carcinomas. J Breast Canc 2009;12:235-240.
8. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol 2008;3:41.
9. Fritzsche FR, Bode PK, Moch H, et al. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH). Am J Surg Pathol 34:1180-1185.
10. Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virch-ows Arch 2007;451:19-25.
11. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
12. Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 2005;7: R267-R273.
13. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 2008;26:4869-4874.
14. Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009;219:16-24.
15. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Am J Clin Pathol 2005;123:237-243. (Pubitemid 40194085)
16. Laakso M, Tanner M, Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol 2006;210:3-9. (Pubitemid 44288174)
17. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131:18-43. (Pubitemid 46174133)
18. van de Vijver M, Bilous M, Hanna W, et al. Chromo-genic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res 2007;9:R68.
19. Dal Lago L, Durbecq V, Desmedt C, et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 2006;5:2572-2579. (Pubitemid 44650922)
20. Powell RD, Pettay JD, Powell WC, et al. Metallo-graphic in situ hybridization. Hum Pathol 2007;38: 1145-1159.
21. Papouchado BG, Myles J, Lloyd RV, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 2010;34:767-776.